José Luis Perez‐Gracia

Author

Also Known As

Amaia Sandúa, Gracia, Jose L. Perez, J L Perez-Gracia, J L Pérez-Gracia, J. Gracia, J. L. Perez Gracia, J. L. Perez-Gracia, J. L. Pérez Gracia, J. L. Pérez-Gracia, J. Perez-Gracia

514

Publications

29.2K

Citations

H-Index

109

Concepts

All Affiliations

Clinica Universidad de Navarra Universidad de Navarra Centro de Investigación Biomédica en Red de Cáncer Navarre Institute of Health Research Yale University

About

José Luis Perez‐Gracia is an author at Clinica Universidad de Navarra specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	63	18.7K
2	Health Sciences	9	9	6.7K
3	Public Health	3	3	57
4	Natural Sciences	1	1	57
5	Allergy	1	1	170

José Luis Perez‐Gracia

132

Publications

24.7K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Roy S. Herbst, Paul Baas, Dong‐Wan Kim, The Lancet Pembrolizumab Versus DocetaxelOncologyClinical TrialsImmune Checkpoint InhibitorPharmacotherapy	2015	6.4K
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, The Lancet UrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2016	3.7K
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, The Lancet UrologyGenitourinary CancerMedicineFirst-line TreatmentCancer Treatment	2016	2.2K
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C Bruno Sangro, Carlos Gómez-Martín, Manuel de la Mata, Journal of Hepatology HepatologyViral HepatitisMedicineImmunologyPathology	2013	977
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity Álvaro Teijeira, Saray Garasa, María Gato, Immunity InflammationCytokineImmune CytotoxicityGranulocyteImmunology	2020	718
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma Kurt A. Schalper, María E. Rodríguez-Ruiz, Ricardo Díez-Valle, Nature Medicine Neuro-oncologyCancer ImmunosurveillanceMedicineImmunologyTumor Immunity	2019	642
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors Kurt A. Schalper, Michael Carleton, Ming Zhou, Nature Medicine InflammationCytokineImmune EvasionCancer ImmunosurveillanceAutoimmune Disease	2020	515
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy Elísabeth Pérez-Ruiz, Luna Minute, Itziar Otano, Nature	2019	465
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients Miguel F. Sanmamed, José Luis Perez‐Gracia, Kurt A. Schalper, Annals of Oncology Cancer ImmunosurveillanceAnti-pd-1 TreatmentMedicineMelanomaImmunology	2017	442
Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs) Carlos Alfaro, Álvaro Teijeira, Carmen Oñate, Clinical Cancer Research	2016	398

Page 1